News
12-13-2010, 06:10 AM
The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial. Details of these study results were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12...
More... (http://mnt.to/f/3NWV)
More... (http://mnt.to/f/3NWV)